In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

M235T polymorphism of ATG: prognostic marker of cardiovascular events in diabetic patients with heart failure with preserved ejection fraction, a 2 year follow-up.

Session Poster Session 7

Speaker Olena Medentseva

Congress : ESC Congress 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P6523

Authors : O Medentseva (Kharkiv,UA), IS Rudyk (Kharkiv,UA), MM Udovychenko (Kharkiv,UA), IG Kravchenko (Kharkiv,UA), SN Pivovar (Kharkiv,UA), GV Bolotskykh (Kharkiv,UA), TV Lozyk (Kharkiv,UA), TG Ovrakh (Kharkiv,UA), TN Bondar (Kharkiv,UA)

O. Medentseva1 , I.S. Rudyk1 , M.M. Udovychenko1 , I.G. Kravchenko1 , S.N. Pivovar1 , G.V. Bolotskykh1 , T.V. Lozyk1 , T.G. Ovrakh2 , T.N. Bondar3 , 1L.T.Malaya Institute of Therapy, Department of Clinical Pharmacology and Pharmagenetics of non-communicable diseases - Kharkiv - Ukraine , 2L.T.Malaya Institute of Therapy, Department of Atherosclerosis and ischemic heart disease - Kharkiv - Ukraine , 3L.T.Malaya Institute of Therapy, Laboratory of Immunochemical and Molecular Research - Kharkiv - Ukraine ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1389-1390

Background: It has been shown a strong influence of ATG polymorphism on heart failure development. However, the impact of M235T polymorphism of ATG on cardiovascular events development in diabetic patients with heart failure with preserved ejection fraction (HFpEF) is still unknown.

Aim: To estimate whether M235T polymorphism of ATG is associated with cardiovascular events in diabetic patients with heart failure with HFpEF.

Methods: A total of eighty-two patients (50 females and 32 males; mean age 62,9±8,1 years) with HFpEF and type 2 diabetes mellitus were examined. Sixty-two patients were carriers of 235T allele (MT+TT genotypes), 20 patients had MM genotype of M235T polymorphism of ATG, which was determined by using of polymerase chain reaction. The pre-defined composite endpoint of cardiovascular events includes cardiac death, hospitalization for heart failure, non-fatal stroke. The Kaplan-Meier method and the log-rank statistic for survival curves evaluation were used.

Results: 40 (48%) patients had the study composite endpoint after mean follow-up of two years. Survival curves showed higher level of cardiovascular events occurrence in patients carrying MT and TT genotypes compared with MM carriers (p=0.01) (Fig.1). In a Cox hazards survival model, the presence of the MT+TT genotypes in diabetic patients with HFpEF was associated independently with higher hazard ratio compared with carriers of MM genotypes (OR 10.30, 95% CI [2.72–39.08], p<0.005).

Conclusion: MT+TT genotypes of M235T polymorphism of ATG were independently associated with worse cardiovascular prognosis in diabetic patients with HFpEF

Figure 1

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are